Compare TPC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | NUVB |
|---|---|---|
| Founded | 1894 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2003 | N/A |
| Metric | TPC | NUVB |
|---|---|---|
| Price | $88.08 | $5.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $82.00 | $11.44 |
| AVG Volume (30 Days) | 549.0K | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 5.15 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $4,326,922,000.00 | N/A |
| Revenue This Year | $25.77 | $659.84 |
| Revenue Next Year | $14.81 | $180.43 |
| P/E Ratio | $88.76 | ★ N/A |
| Revenue Growth | ★ 11.51 | N/A |
| 52 Week Low | $18.34 | $1.57 |
| 52 Week High | $89.40 | $9.75 |
| Indicator | TPC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 67.47 | 46.80 |
| Support Level | $80.00 | $5.12 |
| Resistance Level | $89.40 | $6.22 |
| Average True Range (ATR) | 3.93 | 0.34 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 91.60 | 58.93 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.